Abbott
33,265.00
+325.00(+0.99%)
Market Cap₹70,685.80 Cr
PE Ratio48.63
IndustryHealthcare
Company Performance:
1D+0.99%
1M-3.00%
6M+19.49%
1Y+22.96%
5Y+101.99%
View Company Insightsright
More news about Abbott
01Aug 25
Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits
Abbott India Limited has been penalized Rs. 2 lakh by the Reserve Bank of India for violating foreign exchange laws. The violation occurred when foreign investment in the company exceeded 75% without prior government approval. The RBI issued a Compounding Order on July 31, 2025, concluding the compounding process. Abbott India will deposit the penalty amount and can now receive foreign institutional investments up to the prescribed limit.
16May 25
Abbott India's Q4 Profit Surges, Beats Estimates
Abbott India Ltd reported strong Q4 financial results, surpassing market expectations. Net profit increased by 14.7% to ₹359.00 crore, revenue rose by 9% to ₹1,633.00 crore, and EBITDA grew by 15% to ₹439.00 crore. The company's stock gained nearly 4% following the announcement, reaching ₹31,500.00 per share.
15May 25
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed
Abbott India's Q4 results show strong growth with net profit up 27.90% to ₹367.00 crore, revenue increasing 11.50% to ₹1,604.60 crore, and EBITDA rising 30.00% with margin expansion to 26.70%. The company has recommended a final dividend of ₹475.00 per share, subject to shareholder approval.
Abbott
33,265.00
+325.00
(+0.99%)
1 Year Returns:+22.96%
Industry Peers
Sun Pharmaceutical
1,641.40
(+0.10%)
Divis Laboratories
6,132.50
(+0.52%)
Cipla
1,564.00
(+0.19%)
Torrent Pharmaceuticals
3,623.00
(+0.14%)
Dr Reddys Laboratories
1,260.40
(+0.56%)
Mankind Pharma
2,472.60
(+0.27%)
Zydus Life Science
988.80
(+0.02%)
Lupin
1,961.60
(-1.42%)
Abbott
33,265.00
(+0.99%)
Alkem Laboratories
5,347.50
(-0.76%)